免疫检查点抑制剂联合免疫增强剂治疗恶性肿瘤的研究进展

Advancements in the treatment of malignancies using a combination of immune checkpoint inhibitors and immunomodulators

近年来,肿瘤免疫治疗取得重大突破,以免疫检查点抑制剂为基础的免疫治疗已成为晚期恶性肿瘤的重要治疗手段。免疫治疗已被国内外指南广泛推荐并应用于临床治疗,但其临床治疗效果仍不够理想。如何提高晚期恶性肿瘤病人的免疫治疗效果仍是目前的研究热点。研究表明,免疫增强剂与免疫检查点抑制剂联合应用于多种晚期恶性肿瘤,明显改善免疫治疗的效果。本篇文章重点介绍免疫增强剂与免疫检查点抑制剂联合应用在肿瘤治疗的相关研究,展望免疫增强剂联合免疫检查点抑制剂在肿瘤治疗中的应用前景。

In recent years,there have been significant advancements in tumor immunotherapy.Immune checkpoint inhibitors have emerged as a pivotal approach for treating advanced malignant tumors.The use of immunotherapy has been widely recommended and applied in clinical treatment both domestically and internationally.However,its clinical treatment efficacy still falls short of expectations.Improving the efficacy of immunotherapy for patients with advanced malignant tumors is currently a prominent research focus.Studies indicate that the combined use of immune enhancers and immune checkpoint inhibitors in various advanced malignant tumors significantly enhances the outcomes of immunotherapy.This article primarily highlights the combined application of immune enhancers and immune checkpoint inhibitors in cancer therapy,offering insights into their potential in the field of oncology treatment.